Kiadis Pharma : announces results of Extraordinary General Meeting of Shareholders

Amsterdam-Duivendrecht, The Netherlands, April 4, 2017 - Kiadis Pharma N.V. ('Kiadis
Pharma' or the 'Company') (Euronext Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company developing innovative T-cell immunotherapy treatments for
blood cancers and inherited blood disorders, announces that at its Extraordinary General
Meeting of Shareholders held today at 10:00 CEST at the Amsterdam Stock Exchange
(Euronext), Beursplein 5, 1012 JW Amsterdam, The Netherlands, all resolutions were duly
passed by the shareholders.

About Kiadis Pharma
Kiadis Pharma is focused on cell-based immunotherapy products for the treatment of blood
cancers and inherited blood disorders. The Company's products have the potential to address
the risks and limitations connected with allogeneic hematopoietic stem cell transplantation
(HSCT), namely Graft-versus-Host-Disease (GVHD), cancer relapse, opportunistic infections
and limited matched donor availability. The Company believes that HSCT could become a firstchoice
treatment for blood cancers, inherited blood disorders and possibly autoimmune
diseases and solid organ transplantations.

On December 5, 2016 at the Annual Meeting of the American Society of Hematology (ASH),
the Company reported positive Phase II results with its lead product ATIR101™ in patients
with blood cancer. The data showed that ATIR101™ significantly reduced Transplant Related
Mortality and significantly improved Overall Survival. In addition, a single dose of ATIR101™
did not elicit grade III-IV GVHD in any patient. Based on these positive results, a Phase III
clinical trial has been initiated. ATIR101™ has been granted Orphan Drug Designations both
in the US and Europe.

The Company's second product candidate, ATIR201™, addresses inherited blood disorders
with an initial focus on thalassemia, a disease which results in destruction of red blood cells
in patients. ATIR201™ Phase I/II clinical development has been initiated recently.

Kiadis Pharma, based in Amsterdam, The Netherlands, was granted an Advanced Therapy
Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data by the
European Medicines Agency (EMA). The Company's shares are listed on Euronext Amsterdam
and Euronext Brussels.

Company Contact:
Arthur Lahr, CEO
Kiadis Pharma
Entrada 231-234
1114 AA Amsterdam-Duivendrecht
The Netherlands
Tel. +31 20 314 02 50
communication@kiadis.com

International Media and Investor Contact:
Mary-Jane Elliott, Lindsey Neville, Hendrik Thys
Consilium Strategic Communications
Tel: +44 (0) 203 709 5708
kiadis@consilium-comms.com

Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which
reflect Kiadis Pharma's or, as appropriate, Kiadis Pharma's directors' current expectations
and projections about future events. By their nature, forward-looking statements involve a
number of risks, uncertainties and assumptions that could cause actual results or events to
differ materially from those expressed or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the outcome and financial effects
of the plans and events described herein. A multitude of factors including, but not limited to,
changes in demand, competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development. Forward looking statements
contained in this press release regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the future. As a result, Kiadis
Pharma expressly disclaims any obligation or undertaking to release any update or revisions
to any forward-looking statements in this press release as a result of any change in
expectations or any change in events, conditions, assumptions or circumstances on which
these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or
representatives nor any of its subsidiary undertakings or any such person's officers or
employees guarantees that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the future accuracy of the
forward-looking statements contained in this press release or the actual occurrence of the
forecasted developments. You should not place undue reliance on forward-looking
statements, which speak only as of the date of this press release.